Abstract:Optimal nutrition, driven by a healthy diet, is critical for preventing and treating type 2 diabetes (T2D).1 Moreover, dietary factors closely interact with the gut microbiome to modulate human metabolic health in general, but particularly those related to T2D.2-4 However, considerable interindividual heterogeneity has been observed in response to different foods and the potential development of T2D.5, 6 This implies that the current “one-size-fits-all” dietary recommendations do not meet specific individual needs. Moreover, even the traditional randomized controlled trials, which may be informative about the efficacy of a specific dietary treatment for a group of individuals, cannot tell whether the treatment will be effective at the individual level.4, 7 These limitations call for new approaches in precision nutrition, an emerging field of nutritional science.8 Nutrigenetics has been the workhorse of precision nutrition. Its objective is to evaluate the different phenotypic responses to specific diets, depending on an individualʼs genetic makeup.7 This research has been essential to advance our understanding of the interplay between genetics, nutrition, and health. Despite the heterogeneity of results in the scientific literature, there are several convincing examples of such gene-diet interactions and the potential value of nutrigenetics.9, 10 Thus, an APOA2 variant showed interaction with dietary saturated fat and obesity, suggesting that individuals carrying a specific APOA2 genotype were especially susceptible to develop obesity in a situation of high saturated fat intake. This interaction has been replicated in populations of different ethnicities.10 Another validated gene-diet interaction relates to the interaction between an obesity genetic risk score, consumption of sugar-sweetened beverages, and obesity risk among different US populations.9 Nevertheless, whereas these gene-diet/nutrition interactions help us to narrow down recommendations to subgroups of individuals based on their genetic commonalities, they still fail to guarantee benefit for each individual. Besides nutrigenetics, recent progress has been made in precision nutrition by integrating information about the microbiota and adding dietary challenges to magnify the interindividual differences in postprandial response.11, 12 A representative study of this kind was the Israeli personalized nutrition cohort, showing that personal and gut microbiome features might help predict an individual postprandial glycemic response to dietary components.11 Similar findings were demonstrated more recently by the PREDICT study.12 However, despite the initial promising results of such an integrated approach, much more research and validations in different populations are needed. N-of-1 clinical trials have a long but mostly unknown history. In the 1950s, the concept of the n-of-1 trial was introduced to clinicians by Hogben and Sim.13, 14 However, it did not catch more widespread attention until the 1990s.15 The design of n-of-1 has been applied in different fields such as psychology, education, and some areas of pharmacology. The repeated-crossover design of an n-of-1 trial is an advantageous approach to compare the effect of two or more interventions for an individual.16 Usually, there are three or more cycles, each with two or more treatment periods. Although some nutritional studies incorporated this concept to investigate an individualʼs response to dietary intervention, there is a lack of well-planned and conducted n-of-1 dietary clinical trials.17 One example of a nutritional n-of-1 clinical trial was the recently published Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR).18 In the WE-MACNUTR, a series of n-of-1 clinical trials were conducted to assess the effect of diets differing in macronutrient composition on postprandial glycemic status at the individual level. A group-level comparison was also conducted via aggregated n-of-1 trial analysis. This proof-of-concept n-of-1 trial supports the feasibility of performing n-of-1 trials in nutritional research, and it may serve as a reference for future similar trials. In addition to the WE-MACNUTR, there are several ongoing nutritional n-of-1 trials.19 These pioneering studies will stimulate its use and significantly contribute to the advancement of precision nutrition. Despite the advantages of n-of-1 clinical trials, the practical complexity of the designs and their specific requirements still represents a significant limitation.16 For example, the n-of-1 clinical trials may not be appropriate for acute conditions or rapidly progressive diseases because of the repeated crossover design. The treatments should have a relatively rapid onset of action, with minimal carryover effects after a short washout period.16 Moreover, the analyses and interpretation of aggregated n-of-1 trials are not as well developed as the traditional randomized controlled trials. Nutritional n-of-1 clinical trials will provide a new angle for research in gut microbiome and diabetes. Prospective cohorts have previously supported the interrelation between the diet-gut microbiome and diabetes development. For example, recent evidence showed that dietary and circulating n-6 fatty acids and fruit intake were associated with gut microbiome composition, contributing to understanding the relation between n-6 fatty acids, fruit intake, and T2D risk2, 3 at the population level.2, 3 However, the value of these associations to the individual remains uncertain. Nutritional n-of-1 clinical trials provide a unique opportunity for researchers to characterize the effect of nutritional interventions at the individual level. This approach will disentangle the complex diet-gut microbiome associations with high resolution at the individual level. Moreover, the collection of data over time will provide new knowledge regarding the intrinsic variability and the responses of the gut microbiota. Nevertheless, novel methodological developments are still needed concerning gut microbiome research and its incorporation in n-of-1 trials. The WE-MACNUTR n-of-1 trials, therefore, provided a proof of concept to investigate the effect of diet on the gut microbiome and diabetes traits at the individual level. The primary aim was to test the effect of different macronutrient intake on postprandial glycemic status and identify and classify the individual responses. A secondary aim was to identify those individual responses to macronutrient intake concerning the gut microbiota. Aggregated n-of-1 analytic strategies, as implemented in the WE-MACNUTR, will allow us to do analyses at the group level, similar to the traditional randomized controlled trials. Therefore, the n-of-1 approach will precisely depict the diet-gut microbiome-glycemic status network at either individual or group level. In the WE-MACNUTR,18 researchers used a Bayesian analysis model with noninformative priors to estimate the posterior probability (80% was used as a threshold) of a clinically meaningful difference in three postprandial glycemic outcomes after the intervention of two dietary patterns for each of the involved 28 young Chinese participants (low-fat, high-carbohydrate diet vs high-fat, low-carbohydrate diet). Three outcomes included maximum postprandial glucose, mean amplitude of glycemic excursion and area under the curve24. Finally, nine participants were identified as high-carbohydrate responders (having higher postprandial glycemic status after the low-fat, high-carbohydrate diet compared with the other dietary pattern) and six participants as high-fat responders (the other way round, more sensitive to a low-carbohydrate high-fat diet in increasing postprandial glycemic status). The results from the WE-MACNUTR emphasized the high variability in postprandial glycemic response among individuals and supported the feasibility of n-of-1 trials to characterize the personal response to dietary intervention. Precision nutrition has been the focus of the recently released 2020-2030 Strategic Plan for US National Institutes of Health (NIH) Nutrition Research, as a strategic effort from NIH to improve health and combat nutrition-related chronic diseases.8, 20 The central aim is to set a personalized dietary recommendation for each individual. Integration of n-of-1 clinical trials in nutrition research fits the emerging needs of the precision nutrition initiative. The application of nutritional n-of-1 clinical trials may be an advantageous method for nutrition-microbiome and nutrition-diabetes-related research. Determination of optimal personalized nutritional strategies based on these trials will be an essential step toward precision prevention and treatment of diabetes in clinics in the near future. This work was funded by the National Natural Science Foundation of China (81903316, 81773416), Zhejiang Province Ten-thousand Talents Program (2019R52039). The authors declare no potential conflict of interest.

Clinical Pharmacokinetics of Teicoplanin

The adjuvant activity of CpG DNA requires T-bet expression in dendritic cells.

The patient, the prescription, the problem. Corticosteroid therapy in otolaryngology.

A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases

A methodological review of randomised n-of-1 trials

Biomarkers for Personalizing IBD Therapy: The Quest Continues

The development of a set of key points to aid clinicians and researchers in designing and conducting n-of-1 trials

[Two methods of laparoscopic varicocelectomy for the treatment of spermatic varicocele].

P952 Why do patients with Inflammatory Bowel Disease Take Part in Pharmaceutical Clinical Trials? A qualitative study of Clinical Trial Participants

Navigating the complexities of drug development for inflammatory bowel disease

StudyU: a platform for designing and conducting innovative digital N-of-1 trials

The state-of-the-art of N -of-1 therapies and the IRDiRC N -of-1 development roadmap

Noise figure in UWB systems

Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials

P881 Real-life vs trial access to biologic therapy differences: a 2019-2020 experience in an Italian tertiary IBD center

Personalized Dietary Regimens for Inflammatory Bowel Disease: Current Knowledge and Future Perspectives

"It attracts your eyes and brain": Refining visualizations for shared decision-making with heart failure patients

Food-Based Interventions as Therapy for Inflammatory Bowel Disease: Important Steps in Diet Trial Design and Reporting of Outcomes

Precision Nutrition for Gut Microbiome and Diabetes Research: Application of Nutritional N‐of‐1 Clinical Trials

A qualitative evaluation of treatment fidelity alongside a pilot trial of a novel therapy for pediatric Inflammatory Bowel Disease

Application of N-of-1 Clinical Trials in Personalized Nutrition Research: a Trial Protocol for Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR)